Spruce Street Capital LP Takes $10.96 Million Position in Perspective Therapeutics, Inc. $CATX

Spruce Street Capital LP bought a new position in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) during the 1st quarter, HoldingsChannel reports. The institutional investor bought 2,627,107 shares of the company’s stock, valued at approximately $10,955,000. Perspective Therapeutics comprises approximately 2.6% of Spruce Street Capital LP’s portfolio, making the stock its 15th largest position.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Dimensional Fund Advisors LP boosted its stake in shares of Perspective Therapeutics by 391.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 450,097 shares of the company’s stock valued at $1,877,000 after buying an additional 358,540 shares during the period. Abel Hall LLC purchased a new position in Perspective Therapeutics in the first quarter worth approximately $49,000. Wealth Effects LLC grew its holdings in Perspective Therapeutics by 32.0% during the 1st quarter. Wealth Effects LLC now owns 33,000 shares of the company’s stock worth $138,000 after acquiring an additional 8,000 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Perspective Therapeutics during the fourth quarter worth $84,000. Finally, XTX Topco Ltd lifted its holdings in Perspective Therapeutics by 36.5% during the 4th quarter. XTX Topco Ltd now owns 82,476 shares of the company’s stock worth $227,000 after buying an additional 22,074 shares during the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock opened at $2.91 on Friday. Perspective Therapeutics, Inc. has a 1 year low of $1.96 and a 1 year high of $6.16. The company’s fifty day moving average is $3.31 and its two-hundred day moving average is $3.90.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%.The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. On average, sell-side analysts anticipate that Perspective Therapeutics, Inc. will post -1.1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. BTIG Research reissued a “buy” rating on shares of Perspective Therapeutics in a report on Friday. Eight analysts have rated the stock with a Buy rating, According to MarketBeat, Perspective Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $12.62.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.